Company Overview
Celcuity Inc. operates as a clinical-stage biotechnology company dedicated to the development and commercialization of targeted therapies designed to treat various solid tumors within the United States. The firm's strategic focus centers on its lead drug candidate, Gedatolisib, which functions by selectively targeting specific Class I isoforms of phosphatidylinositol-3 kinase pathways to inhibit tumor growth. This business model places the company squarely within the Healthcare sector, specifically the Biotechnology industry, where it competes in the high-risk, high-reward environment of early-stage drug development. With a market capitalization of $5.23B and an employee count of 87, the company demonstrates a valuation that significantly exceeds its reported financial scale, as the available data indicates no annual revenue figures are provided for this period. This disparity between the substantial market cap and the lack of reported revenue suggests the market is pricing the asset based on future potential and pipeline assets rather than current operational cash flow or sales performance.
Financial Health
The company reports a Net Income (TTM) of $-162,722,112 and an EBITDA of $-159,268,000, while Revenue (TTM) is listed as N/A in the available data. The absence of reported revenue combined with a net income loss of over $162 million reveals a cost structure where expenses, likely driven by research, development, and clinical trial costs, are substantially higher than any current sales generated. Free Cash Flow stands at $-91,554,760, indicating that the company is consuming cash reserves to fund its operations and development activities rather than generating liquidity from its core business. Margins across the board reflect this developmental stage: Gross Margin is 0.0%, Operating Margin is 0.0%, and Profit Margin is 0.0%, which collectively indicate that the company has not yet achieved profitability or generated revenue sufficient to cover its direct and indirect costs. In terms of leverage, the company holds $454.98M in cash against $320.34M in debt, resulting in a Debt to Equity ratio of 273.89, which suggests a highly leveraged balance sheet relative to its equity base. Despite the high debt load, the Current Ratio of 12.26 indicates a robust short-term liquidity position, as the company possesses significantly more current assets than current liabilities. Finally, the Return on Equity is -122.0% and the Return on Assets is -26.6%, metrics that reveal management is currently utilizing shareholder capital and assets to generate negative returns due to the ongoing losses associated with clinical-stage development.
Valuation Assessment
The valuation metrics for Celcuity Inc. present a complex picture, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -25.02. The negative forward P/E implies that the market expects the company to remain unprofitable in the near term, preventing a traditional earnings-based valuation from materializing. The Price to Book ratio is 41.80, which indicates a massive market premium over the company's book value, suggesting investors are willing to pay significantly more than the net asset value based on future clinical successes. Alternative valuation metrics further highlight this premium; the Price to Sales ratio is N/A due to lack of revenue data, while the EV/EBITDA stands at -31.98, reinforcing the negative earnings trajectory. Regarding trading range, the 52-Week High is $120.31 and the 52-Week Low is $7.58; without a specific current price provided in the source data to calculate the exact percentage, the stock trades within a range of approximately 159-fold between its recent highs and lows. The Beta is 0.41, which signifies that the stock price volatility is roughly 59% lower than the broader market, making it less sensitive to general market swings compared to high-beta equities.
Growth & Income
Celcuity Inc. reports Revenue Growth (YoY) as N/A and Earnings Growth (YoY) as N/A, reflecting the early-stage nature of the business where historical growth rates are not yet established. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all of its earnings—however negative—to reinvest into its clinical pipeline and research initiatives. The company reinvests its limited resources into growth rather than paying dividends to shareholders, a strategy typical for biotechnology firms in the clinical stage. Overall, the growth and income profile is characterized by a complete lack of current income generation and undefined historical growth rates, focusing entirely on the potential for future value creation from the Gedatolisib candidate.